Skip to contentV
Vistagen Therapeutics, Inc.
V
VTGNVistagen Therapeutics, Inc. Q2 2017 · 10-Q
Revenue$0.00$0.00no prior Q2 2016 on file Net Income-$3.10M-$3.10MN/M vs Q2 2016 EPS Diluted-$0.42-$0.42N/M vs Q2 2016 Operating Income-$3,099,700N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vistagen Therapeutics, Inc. · CIK 1411685 · Engraved from SEC EDGAR
derived
ended Sep 30, 2016 · filed Nov 14, 2016 · 45 d after period end